Life Threatening Gastrointestinal Tumour More Common Than Suspected
The incidence of gastrointestinal stromal tumours (GISTs), generally considered a rare sarcoma, is more than three times as high as previously believed, according to data presented in Nice at the 27th annual European Society of Medical Oncology (ESMO) Congress. An accurate estimate of GIST incidence has been elusive because of diagnostic ambiguities, now largely resolved by modern immunohistochemistry.
The higher incidence of GIST – calculated at 16 per 1,000,000 people annually – is especially significant because there is now an effective treatment for GIST, the oral therapy imatinib, formerly known as STI 571. The availability of an effective therapy makes it vital to accurately diagnose the disease.
The study, the first population-based examination of the incidence of GIST, was presented by a team headed by Lars-Gunnar Kindblom, MD, PhD, of Sahlgrenska Academy at Göteborg University, Sweden. The team analyzed the medical records and tissue blocks of patients seen from 1983 to 2000 and found 400 cases of true GIST. This was more than three times as many as originally diagnosed. The reanalysis relied in large part on CD 117 (Kit) immunohistochemistry, which Dr. Kindblom pioneered over the past three years. He recommended wider use of CD 117 (Kit) staining for gastrointestinal tumours. Kit receptors in these tumours are the telltale signs of GIST.
“GIST is much more common than we thought, and it is crucial to get the diagnosis right,” Dr. Kindblom said. “Surgeons and pathologists should know that GIST incidence is greater than they had suspected. There is striking variability in the appearance of these tumours, and CD 117 stains for Kit receptors should be widely applied to provide physicians and patients with the best tumour-specific diagnoses, leading to targeted therapeutic options.”
Dr. Kindblom noted that many of the patients in his team’s population-based study who are still living have become candidates for treatment with imatinib.
Historically, GIST has been extremely difficult to treat because of its resistance to treatment with chemotherapy and radiation therapy; surgery to remove GISTs is considered palliative. Imatinib is a targeted treatment for Kit-positive GIST. Imatinib was approved in May 2002 in the European Union, and is also available in many other countries worldwide for the treatment of patients with Kit (CD 117)-positive unresectable (inoperable) and/or metastatic malignant GISTs. An annual incidence of 16 per 1,000,000 means nearly 1,000 new GIST cases per year in France, or about 4,000 new cases per year in the U.S.
The study owes its existence not only to the recent development of CD 117 staining for Kit receptors by Dr. Kindblom but also to the organization of the medical system in southwestern Sweden, where 1.5 million people live. In that part of Sweden, all histology analyses of sarcomas are done in just four laboratories, making their reanalyses manageable.
Carina Elmäng | alfa
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
Next-generation gravitational wave detector in space will complement LIGO on Earth
The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...
A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.
The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...